Advertisement
U.S. markets open in 5 hours 54 minutes

Bayer Aktiengesellschaft (BAYRY)

Other OTC - Other OTC Delayed Price. Currency in USD
7.10-0.04 (-0.56%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.14
Open7.16
Bid0.00 x 0
Ask0.00 x 0
Day's Range7.09 - 7.16
52 Week Range7.02 - 17.00
Volume2,059,597
Avg. Volume1,600,521
Market Cap28.045B
Beta (5Y Monthly)0.97
PE Ratio (TTM)N/A
EPS (TTM)-0.81
Earnings DateN/A
Forward Dividend & Yield0.66 (9.30%)
Ex-Dividend DateMay 02, 2023
1y Target Est28.89
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BAYRY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BAYER AG SPON ADR EACH REP 0.25
    Analyst Report: Bayer AktiengesellschaftBayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.
    Rating
    Fair Value
    Economic Moat
    13 days agoMorningstar
View more
  • Yahoo Finance Video

    Bayer CEO: Now is not the time to break the company up

    Life sciences company Bayer (BAYRY, BAYN.DE) isn't breaking itself up right now. Bayer CEO Bill Anderson says, "This is not a good time to be... breaking up the firm," given the company's need to rebuild its pharmaceutical pipeline and battle the ongoing litigation stemming from the weedkiller Roundup. When it comes to the Roundup lawsuits, Bayer has "adequately provisioned" for the costs of those suits, Anderson says. Overall, "the fundamental fact is, that glyphosate, Roundup, is safe," Anderson states, adding that Bayer is "a scientifically-driven company and we have this litigation thing that's not scientific." On the pharmaceutical business, Anderson says the group is "in a bit of a transition phase." "We got a couple of major medicines that are losing patent protection over the next few years. So we are busy rebuilding the pipeline right now," he tells Yahoo Finance. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.

  • Yahoo Finance Video

    Inflation: Over-the-counter drug prices leap year over year

    Alongside other sectors of the consumer economy, nonprescription drug prices saw prices rise 9.3% year-over-year. The insurance industry, health insurance and auto insurance providers in particular, have been beset by inflationary challenges. Yahoo Finance Health Reporter Anjalee Khemlani details the price trends for over-the-counter drugs, referencing a statement from Bayer (BAYRY) from its third-quarter 2023 in relation to how pharmaceutical companies are trying to offset inflation. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.

  • Reuters

    Bayer rejects Brazilian farmers' claim that court finds it liable for $2 bln in royalties

    Bayer rejected on Tuesday a claim by a Brazilian farmers' lobby group that the country's top court had ordered the diversified German company to return about $2 billion in royalties to soybean farmers. The case, which is related to a law dispute in Brazil about extensions of patents for more than 20 years, is the latest chapter of a protracted battle between Bayer and Brazilian farmers, who have launched multiple legal challenges against the company. Mato Grosso state farmer lobby Aprosoja-MT said in a statement the Supreme Court ordered Bayer on Tuesday to return to farmers royalties they have paid since 2018 related to two patents of genetically modified organism known as Intacta RR2 PRO.